Asim F Belgaumi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2459461/publications.pdf

Version: 2024-02-01

623734 677142 61 566 14 22 citations h-index g-index papers 61 61 61 947 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Clinical characteristics and outcome of children with biphenotypic acute leukemia. Haematologica, 2009, 94, 1682-1690.	3.5	80
2	Impact of the coronavirus disease 2019 (COVIDâ€19) pandemic on pediatric oncology care in the Middle East, North Africa, and West Asia region: A report from the Pediatric Oncology East and Mediterranean (POEM) group. Cancer, 2020, 126, 4235-4245.	4.1	67
3	Dexamethasone-associated toxicity during induction chemotherapy for childhood acute lymphoblastic leukemia is augmented by concurrent use of daunomycin. Cancer, 2003, 97, 2898-2903.	4.1	64
4	Hodgkin lymphoma in very young children: Clinical characteristics and outcome of treatment. Leukemia and Lymphoma, 2008, 49, 910-916.	1.3	23
5	Clinical features and induction outcome of childhood acute lymphoblastic leukemia in a lower/middle income population: A multi-institutional report from Pakistan. Pediatric Blood and Cancer, 2015, 62, 1700-1708.	1.5	21
6	The Impact of Socioeconomic Factors on the Outcome of Childhood Acute Lymphoblastic Leukemia (ALL) Treatment in a Low/Middle Income Country (LMIC). Journal of Pediatric Hematology/Oncology, 2016, 38, 587-596.	0.6	21
7	Cancer in Sotos Syndrome: Report of a Patient With Acute Myelocytic Leukemia and Review of the Literature. Journal of Pediatric Hematology/Oncology, 2004, 26, 204-208.	0.6	20
8	Predictors of treatment abandonment for patients with pediatric cancer at Indus Children Cancer Hospital, Karachi, Pakistan. Pediatric Blood and Cancer, 2018, 65, e26818.	1.5	20
9	Pediatric Lymphoma: A 10-year Experience at a Tertiary Care Hospital in Pakistan. Journal of Pediatric Hematology/Oncology, 2010, 32, e14-e18.	0.6	18
10	Epstein – Barr virus infection is not the sole cause of high prevalence for Hodgkin's lymphoma in Saudi Arabia. Leukemia and Lymphoma, 2006, 47, 707-713.	1.3	17
11	INVASIVE CHAETOMIUM INFECTION IN TWO IMMUNOCOMPROMISED PEDIATRIC PATIENTS. Pediatric Infectious Disease Journal, 2007, 26, 456-458.	2.0	17
12	Clinical characteristics and treatment outcome of childhood acute lymphoblastic leukemia in Saudi Arabia: A multiâ€institutional retrospective national collaborative study. Pediatric Blood and Cancer, 2014, 61, 74-80.	1.5	17
13	Chimerism Analysis of Cell-Free DNA in Patients Treated with Hematopoietic Stem Cell Transplantation May Predict Early Relapse in Patients with Hematologic Malignancies. Biotechnology Research International, 2016, 2016, 1-6.	1.4	17
14	Childhood cancer care in the Middle East, North Africa, and West/Central Asia: A snapshot across five countries from the POEM network. Cancer Epidemiology, 2021, 71, 101727.	1.9	17
15	Clinical characteristics and treatment outcome of pediatric patients with chronic myeloid leukemia. Haematologica, 2010, 95, 1211-1215.	3.5	15
16	Incidence, clinical distribution, and patient characteristics of childhood cancer in Saudi Arabia: A populationâ€based analysis. Pediatric Blood and Cancer, 2019, 66, e27684.	1.5	13
17	Stability and sterility of a recombinant factor viii concentrate prepared for continuous infusion administration., 1999, 62, 13-18.		11
18	Riskâ€adapted stratification for optimally intensive treatment assignment of pediatric patients with nonâ€Hodgkin lymphoma is an effective strategy in developing countries. Pediatric Blood and Cancer, 2017, 64, e26335.	1.5	9

#	Article	IF	CITATIONS
19	Outcome of pediatric patients with lymphoma following stem cell transplant: a single institution report. Leukemia and Lymphoma, 2015, 56, 1327-1334.	1.3	8
20	Improved outcome for children with acute lymphoblastic leukemia after risk-adjusted intensive therapy: a single-institution experience. Annals of Saudi Medicine, 2008, 28, 251-259.	1.1	8
21	Childhood acute lymphoblastic leukemia presenting with severe hepatic dysfunction. Medical and Pediatric Oncology, 2001, 37, 142-144.	1.0	7
22	Megakaryocytic blast crisis at presentation in a pediatric patient with chronic myeloid leukemia. Hematology/ Oncology and Stem Cell Therapy, 2010, 3, 42-46.	0.9	6
23	Erdheim Chester disease–An unusual presentation of a rare histiocytic disease in a 3-year old boy. Pediatric Hematology Oncology Journal, 2017, 2, 59-62.	0.1	6
24	The Pediatric Oncology East and Mediterranean (POEM) group $\hat{a}\in$ A regional collaborative platform for childhood cancer healthcare professionals. Pediatric Hematology Oncology Journal, 2020, 5, 3-6.	0.1	6
25	Pediatric oncology infrastructure and workforce training needs: A report from the Pediatric Oncology East and Mediterranean (POEM) Group. Pediatric Blood and Cancer, 2021, 68, e29190.	1.5	6
26	High throughput tissue microarray analysis of FHIT expression in diffuse large cell B-cell lymphoma from Saudi Arabia. Modern Pathology, 2006, 19, 1124-1129.	5.5	5
27	Clinical characteristics and outcome of pediatric patients with stage IV Hodgkin lymphoma. Hematology/ Oncology and Stem Cell Therapy, 2009, 2, 278-284.	0.9	5
28	Outcome of allogeneic stem cell transplantation with a conditioning regimen of busulfan, cyclophosphamide and low-dose etoposide for children with myelodysplastic syndrome. Hematology/Oncology and Stem Cell Therapy, 2011, 4, 121-125.	0.9	5
29	Pediatric hematology oncology during SARSâ€CoVâ€2: A brief communication of 28 patients and changes in clinical practice from a single institute in Pakistan. Pediatric Blood and Cancer, 2021, 68, e28527.	1.5	5
30	CD64 Expression Is An Independent Adverse Prognostic Factor in Pediatric Acute Myeloid Leukemia Treated with Allogeneic Stem Cell Transplantation,. Blood, 2011, 118, 3525-3525.	1.4	5
31	Hodgkin's lymphoma in the young child. Transfusion and Apheresis Science, 2010, 42, 163-167.	1.0	4
32	Discrepancies between DNA index by flow cytometry and cytogenetic studies in childhood B-Lymphoblastic leukemia. Journal of Applied Hematology, 2018, 9, 45.	0.3	4
33	Precursor B-cell lymphoblastic lymphoma (PBLL) in children: pattern of presentation and outcome. Journal of the Egyptian National Cancer Institute, 2005, 17, 15-9.	1.5	4
34	Treatment of a clinically determined lower-risk stage III non-lymphoblastic non-hodgkin lymphoma with less intensive therapy does not impact negatively on outcome. Pediatric Blood and Cancer, 2006, 46, 367-371.	1.5	3
35	Outcome of risk adapted therapy for relapsed/refractory acute lymphoblastic leukemia in children. Leukemia and Lymphoma, 2013, 54, 547-554.	1.3	3
36	Favorable Response to Treatment of a Child With T-Cell-Rich Large B-Cell Lymphoma Presenting With Liver Failure. Journal of Pediatric Hematology/Oncology, 2003, 25, 809-812.	0.6	2

#	Article	IF	Citations
37	Pediatric Hodgkin's lymphoma: Changing concepts and moving points in radiation therapy. Transfusion and Apheresis Science, 2013, 49, 56-62.	1.0	2
38	Evaluation of Baseline Cardiac Function by Echocardiography and its Association With Nutritional Status in Pediatric Cancer Patients at The Indus Hospital in Karachi, Pakistan. Journal of Pediatric Hematology/Oncology, 2019, 41, e388-e394.	0.6	2
39	Outcome of Second Line Therapy for Pediatric Patients with Hodgkin Lymphoma Who Relapse Following ABVD Based Therapy Blood, 2009, 114, 2691-2691.	1.4	2
40	Pediatric oncology infrastructure and workforce training needs: a report from the Pediatric Oncology East and Mediterranean (POEM) Group. Pediatric Blood and Cancer, 0, , .	1.5	1
41	Pediatric Hodgkin Lymphoma: Making Progress. Current Pediatrics Reports, 2014, 2, 50-59.	4.0	o
42	The contribution of multiple packed red blood cell transfusions toward cardiac and liver dysfunction in pediatric patients with acute myeloid leukemia*. Leukemia and Lymphoma, 2016, 57, 2472-2475.	1.3	0
43	Degree of Concordance between Peripheral Blood Leukemic Blast Count and Mid Induction Bone Marrow in Childhood Acute Lymphoblastic Leukemia Blood, 2004, 104, 4488-4488.	1.4	O
44	Epstein-Barr Virus Infection Is Not the Sole Cause of High Prevalence for Hodgkin's Lymphoma in Saudi Arabia Blood, 2004, 104, 3120-3120.	1.4	0
45	Does High Dose Cytosine Arabinoside Improves Disease Free Survival for Down Syndrome Acute Myelocytic Leukemia Patients? Blood, 2005, 106, 4612-4612.	1.4	0
46	Pediatric Hodgkin Lymphoma Patients Treated with ABVD Chemotherapy with or without Low-Dose Radiation Therapy Blood, 2006, 108, 4672-4672.	1.4	0
47	Hodgkin Lymphoma in Very Young Children Can Be Treated Successfully without Radiation Therapy Blood, 2006, 108, 2472-2472.	1.4	O
48	The Outcome of Children with T-Cell Acute Lymphoblastic Leukemia: A Single Institution Experience Blood, 2006, 108, 4526-4526.	1.4	0
49	Effective Treatment of Biphenotypic Acute Leukemia in Children with Chemotherapy Alone Blood, 2006, 108, 4522-4522.	1.4	O
50	Downs Syndrome Patients with Acute Lymphoblastic Leukemia; an Intermediate Outcome with a High Infectious Morbidity Blood, 2006, 108, 4521-4521.	1.4	0
51	The AG Genotype of the Wilms Tumor-1 rs16754 SNP Is Associated with Poor Outcome in Pediatric AML Patients Treated with Stem Cell Transplantation but Not in Adults. Blood, 2011, 118, 5237-5237.	1.4	O
52	Chimerism Analysis of Free Circulating DNA in the Prediction of Relapse in Patients with Acute Leukemia Treated with Stem Cell Transplantation,. Blood, 2011, 118, 3533-3533.	1.4	0
53	Risk Factors for Acute Graft-Versus-Host Disease After Related Hematopoietic Cell Transplantation in Children with Acute Leukemia. Blood, 2011, 118, 1983-1983.	1.4	0
54	Outcome of Risk Adapted Therapy for Relapsed/Refractory Acute Lymphoblastic Leukemia in Children: Results From a Single Institution. Blood, 2011, 118, 4237-4237.	1.4	0

#	Article	IF	CITATIONS
55	Most Risk-Stratification Molecular Markers in Acute Myeloid Leukemia (AML) Are Rarely Found in Early Childhood AML in the Middle Eastern Population. Blood, 2011, 118, 5239-5239.	1.4	O
56	CD11b Expression Is An Independent Adverse Prognostic Factor in Pediatric Acute Myeloid Leukemia Treated with Allogeneic Stem Cell Transplantation,. Blood, 2011, 118, 4092-4092.	1.4	0
57	Cytogenetic Risk Remains a Major Predictor of Outcome in Pediatric AML and ALL Treated with Allogeneic Stem Cell Transplantation,. Blood, 2011, 118, 3524-3524.	1.4	O
58	Outcome Of Hematopoietic Cell Transplantation (HCT) In Pediatric Patients With Hodgkin Lymphoma (HL): Single Institution Results From Saudi Arabia. Blood, 2013, 122, 5530-5530.	1.4	0
59	Outcome Of Hematopoietic Cell Transplantation (HCT) In Pediatric Patients With Non-Hodgkin Lymphoma (NHL): Single Institution Results From Saudi Arabia. Blood, 2013, 122, 5522-5522.	1.4	O
60	Multiple Packed Red Blood Cell (PRBC) Transfusions In Pediatric Patients With Acute Myeloid Leukemia (AML) Result In a Large Transfusional Iron Dose With The Potential For Long-Term Organ Dysfunction. Blood, 2013, 122, 2660-2660.	1.4	0
61	Development and implementation of a distributed integrated data-management system for pediatric hematology/oncology service: a modular approach for a clinical outcome and research information system. Journal of Registry Management, 2012, 39, 147-53.	0.1	0